Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ALGN stock price vs DHR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Implied fair value · at ALGN's multiple
Needs ALGN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALIGN TECHNOLOGY, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABERCROMBIE & FITCH CO /DE/
ALGN vs ANF
Envista Holdings Corp
ALGN vs NVST
HENRY SCHEIN INC
ALGN vs HSIC
PATTERSON COMPANIES, INC.
ALGN vs PDCO
3M CO
ALGN vs MMM
AGILENT TECHNOLOGIES, INC.
ALGN vs A
ILLUMINA, INC.
ALGN vs ILMN
JOHNSON & JOHNSON
ALGN vs JNJ
ABBOTT LABORATORIES
ALGN vs ABT
LOEWS CORP
ALGN vs L
BERKSHIRE HATHAWAY INC
ALGN vs BRK-B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ALGN can reaccelerate growth and convert its stronger gross margin and ROIC into better operating leverage, then the stock looks attractive relative to DHR because it trades at lower multiples across every valuation measure; otherwise, DHR’s superior margins and growth justify its premium.
ALGN trades at a clear discount to DHR on P/E, P/S, EV/EBITDA, and EV/Revenue, yet the implied upside of 31.9% is tempered by the fact that DHR already commands higher quality and scale multiples. The market appears to be balancing ALGN’s lower valuation against DHR’s stronger operating margins and broader business profile.
Supporting Metrics
